--- title: Virtual Reality (VR) Diagnostic Tool for Attention Deficits/Hyperactivity Disorder (ADHD) nct_id: NCT04337905 overall_status: UNKNOWN phase: NA sponsor: Tjhin Wiguna study_type: INTERVENTIONAL primary_condition: ADHD countries: Indonesia canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04337905.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04337905" ct_last_update_post_date: 2020-04-08 last_seen_at: "2026-05-12T06:21:29.413Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Virtual Reality (VR) Diagnostic Tool for Attention Deficits/Hyperactivity Disorder (ADHD) **Official Title:** A New Development Diagnostic Tool for ADHD: A VR Approach **NCT ID:** [NCT04337905](https://clinicaltrials.gov/study/NCT04337905) ## Key Facts - **Status:** UNKNOWN - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 100 - **Lead Sponsor:** Tjhin Wiguna - **Collaborators:** Fakultas Kedokteran Universitas Indonesia, Dr Cipto Mangunkusumo General Hospital, Binus University International - **Conditions:** ADHD, Executive Dysfunction - **Start Date:** 2019-05-25 - **Completion Date:** 2021-07-31 - **CT.gov Last Update:** 2020-04-08 ## Brief Summary Attention deficit/ hyperactivity disorder (ADHD) is a common neurodevelopmental disorder. The common diagnostic of ADHD is based on psychiatric examination and interview. So far, there is not any other diagnostic tool for ADHD nowadays. Therefore, virtual reality (VR) technology can be used as a stimulus, replacing real stimuli, recreating experiences, which are in the real world would be impossible. Consequently, ADHD-VR diagnostic tool development should be started to justify the ADHD diagnosis in psychiatric out-patient clinical services. ## Detailed Description Diagnostic test is a very essential in modern medical practices, especially in child and adolescent psychiatry field because the main diagnostic tool is only based on psychiatry interview and observation. Using Diagnostic tool can help a confirmation towards specific clinical diagnosis, provide more evidence for eliminating one diagnosis versus another, provide more evidence for parents, or to rule out the differential diagnosis. Even though psychiatric examination is the main approach on ADHD diagnostic procedure, however the laboratory testing or imaging examination is also used especially to rule out the general medical condition or to find out any medical conditions that mimic ADHD but not to facilitate the ADHD diagnosis per se. Nowadays, the expand study in biological psychiatry has found a lot of biological markers in ADHD as well; but none is really sensitive and specific for ADHD diagnostic test. Therefore, there should be another approach for developing diagnostic tool in ADHD. VR is one of the best approach bacasue these days, because VR as an ADHD diagnostic tool could create and replace real stimuli, recreating experiences, which could not be observed by the clinician at the out-patient clinic. ## Eligibility - **Minimum age:** 6 Years - **Maximum age:** 17 Years - **Sex:** ALL - **Healthy Volunteers:** Yes ``` Inclusion Criteria for ADHD group: * Children with ADHD drug naive * Parent willing to participate in the study by signing informed consent * Children willing to participate the ADHD-VR diagnostic tool for at least 30 minutes Exclusion Criteria: * Having untreated chronic physical illnesses * Having other mental disorders except ADHD Inclusion Criteria for healthy children group: * Do not have any mental disorder * Do not have untreated chronic physical illnesses * Parent willing to participate in the study by signing informed consent * Children willing to participate the ADHD-VR diagnostic tool for at least 30 minutes ``` ## Arms - **Children with ADHD** (EXPERIMENTAL) — Children with ADHD that running the ADHD-VR diagnostic test and also did the psychiatric examination to determine the ADHD diagnosis and to rule out other mental disorders - **Children without ADHD** (ACTIVE_COMPARATOR) — Healthy children that also running the ADHD-VR diagnostic test and also psyhchiatric examination to rule out the ADHD diagnosis and other mental disorders ## Interventions - **ADHD-VR diagnosis tool** (DEVICE) — Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as "real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation"; Gigante (1993) described VR as "The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience"; and "Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments". ## Primary Outcomes - **The sensitivity and specificity of ADHD-VR diagnostic tool towards ADHD clinical symptoms** _(time frame: up to 30 minutes)_ — The comparing between the ADHD-VR diagnostic test results and expert judgement on ADHD diagnosis - **The sensitivity and specificity of ADHD-VR diagnostic tool towards executive function** _(time frame: up to 30 minues)_ — Comparing between the ADHD-VR diagnostic test results and Behavior Rating Inventory for Executive Function Rating Scale. ## Locations (1) - dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia ## Recent Field Changes (last 30 days) - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.dr. cipto mangunkusumo general hospital|jakarta pusat|dki jakarta|indonesia` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04337905.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04337905* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*